The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined bt the SGRQ and the effect on COPD...
Date First Received: April 17, 2008
Last Updated: July 29, 2008
Verified by: Boehringer Ingelheim Pharmaceuticals, July 2008
Clinical Trial Phase: Phase 3 | Start Date: April 2008
Overall Status: Recruiting
Estimated Enrollment: 140
Brief Summary
Official Title: “Tiotropium/Salmeterol Inhalation Powder in COPD”
Condition Keyword(s):
Intervention(s):
The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined bt the SGRQ and the effect on COPD exacerbations
Study Type: Interventional
Study Design: Crossover Assignment, Safety/Efficacy Study
Study Primary Completion Date: August 2009
Intervention(s) in this Clinical Trial
- Drug: Tiotropium/Salmeterol
- Tiotropium/Salmeterol 7.5/25 mcg
- Drug: Tiotropium
- Tiotropium 18 mcg
- Drug: Salmeterol
- Salmeterol 25 mcg
Outcome Measures for this Clinical Trial
Primary Measures
- Trough FEV1 response
FEV1AUC 0 8hr response
Mahler TDI focal score
SGRQ total score
Time to first moderate to severe COPD exacerbation
- Time Frame: 12 Weeks, 24 Weeks and 48 Weeks
- Time Frame: 12 Weeks, 24 Weeks and 48 Weeks
Secondary Measures
- Trough FVC response
FVCAUC 0 8h response
PEF
Use of rescue medication
COPD related night time awakenings
- Time Frame: 4 Weeks, 12 Weeks, 24 Weeks 36 Weeks and 48 Weeks
- Time Frame: 4 Weeks, 12 Weeks, 24 Weeks 36 Weeks and 48 Weeks
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
Main:
- Diagnosis of COPD
- Post-bronchodilator FEV1<80% predicted and FEV1/FVC<70% predicted
Exclusion Criteria:
Main:
- Significant other diseases then COPD
- Recent MI
- Any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the past year
- Hospitalization for cardiac failure during the past year
- History of asthma
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 40 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Boehringer Ingelheim Pharmaceuticals
Overall Clinical Trial Officials and Contacts
Boehringer Ingelheim Study Chair Boehringer Ingelheim Pharmaceuticals
Overall Contact: Boehringer Ingelheim Study Coordinator clintriage@boehringer-ingelheim.com
Additional Information
Information obtained from ClinicalTrials.gov on September 05, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00668772
Study ID Number: 1184.15
ClinicalTrials.gov Identifier: NCT00668772
Health Authority: Brazil: National Health Surveillance Agency
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
